Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
Hospices Civils de Lyon / Hopital de la Croix Rousse, Lyon, France
Department of Ophthalmology, University Hospital Bern, Bern, Switzerland
Inselspital Bern, Department of Ophthalmology, Bern, Switzerland
Department of Ophthalmology, Universtiy of Bonn, Bonn, Germany
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
Rafic Hariri University Hospital, Beirut, Lebanon
Duke Eye Center, Durham, North Carolina, United States
St. Michael's Hospital Eye Clinic, Toronto, Ontario, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.